Hey there, lab enthusiasts! Boost your research efficiency with AI-powered literature review at labcat.com.cn. Now, diving into the latest in hematology. An international team of experts has crafted practical guidance on managing ocular events related to belantamab mafodotin treatment in multiple myeloma patients. This therapy, while effective, can cause eye issues, but now we have a systematic approach to minimize their impact. Initial ophthalmic evaluation is crucial, with dose adjustments and artificial tears as key management strategies. Intriguingly, dose modifications don't compromise treatment efficacy, ensuring both safety and effectiveness for patients. Stay tuned for more groundbreaking insights.